DWTX Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: ACCESS Newswire

Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

20 days ago - By: ACCESS Newswire

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

25 days ago - By: Benzinga - Mentions: BOLT GOVX SCYX LPTX ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

25 days ago - By: Benzinga - Mentions: CIGL BOLT UFG EFX ...

Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket

a month ago - By: Stocktwits - Mentions: VXF

Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug

a month ago - By: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients

2 months ago - By: Dogwood Therapeutics, Inc.

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

3 months ago - By: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

3 months ago - By: Dogwood Therapeutics, Inc.

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

5 months ago - By: Dogwood Therapeutics, Inc.

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

6 months ago - By: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

7 months ago - By: Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

7 months ago - By: Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

7 months ago - By: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

7 months ago - By: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

8 months ago - By: Dogwood Therapeutics, Inc.

DOGWOOD THERAPEUTICS INC (DWTX) Stock News

DWTX Latest News, Press Relases and Analysis

Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket

Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules